Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mutations in the BRAF gene, inhibitors designed speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Crespo-Rodriguez, Eva, Bergerhoff, Katharina, Bozhanova, Galabina, Foo, Shane, Patin, Emmanuel C, Whittock, Harriet, Buus, Richard, Haider, Syed, Muirhead, Gareth, Thway, Khin, Newbold, Kate, Coffin, Robert S, Vile, Richard G, Kim, Dae, McLaughlin, Martin, Melcher, Alan A, Harrington, Kevin J, Pedersen, Malin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445339/
https://www.ncbi.nlm.nih.gov/pubmed/32759235
http://dx.doi.org/10.1136/jitc-2020-000698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445339/
https://www.ncbi.nlm.nih.gov/pubmed/32759235
http://dx.doi.org/10.1136/jitc-2020-000698

Ejemplares similares